sparfosic acid (PALA)

inhibitor of aspartate transcarbamylase

Also Known As:

PALA; N-(phosphonacetyl)-L-aspartate; N-(phosphonoacetyl)-L-aspartate; N-(phosphonoacetyl)-L-aspartic acid; NCI 224131; NSC 224131; NSC 224131, disodium salt; NSC 224131, tetrasodium salt; NSC-224131; l-aspartic acid, n-(2-phosphonoacetyl)-; phosphonoacetyl-l-aspartic acid

Networked: 217 relevant articles (20 outcomes, 64 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gu, Xiaochen: 2 articles (12/2018 - 08/2013)
2.	Li, Juan: 2 articles (12/2018 - 08/2013)
3.	Wang, Guangji: 2 articles (12/2018 - 08/2013)
4.	Wang, Yang: 2 articles (12/2018 - 08/2013)
5.	Montero, Jean-Louis: 2 articles (03/2005 - 10/2003)
6.	Abbruzzese, James L: 2 articles (11/2004 - 08/2004)
7.	Ardalan, Bach: 2 articles (11/2004 - 08/2004)
8.	Balcerzak, Stanley P: 2 articles (11/2004 - 08/2004)
9.	Benedetti, Jacqueline K: 2 articles (11/2004 - 08/2004)
10.	Macdonald, John S: 2 articles (11/2004 - 08/2004)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/21/1999 - "This study investigates the chromosomal alterations involved in the acquisition of PALA resistance of LoVo colorectal cancer cells homozygous for wild-type TP53 before and after transfection with a 143Ala-mutated TP53 gene. " 05/01/1992 - "Two previous studies of patients with colorectal carcinoma documented complete response (CR) and partial response (PR) rates of 40% and 43% using weekly low-dose PALA followed by a 24-hour FU infusion. " 02/01/1980 - "PALA appears inactive in patients with metastatic colorectal carcinoma in the dose and schedule used in this study." 01/21/1999 - "Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers." 10/01/1997 - "PALA/MTX/5-FU in this dose and schedule is active in patients with colorectal cancer. "
2.	Neoplasms (Cancer) 08/01/1976 - "Lewis lung tumors had reached about 500 mg, PALA neither cured the mice nor produced significant tumor regression. " 02/01/1982 - "PALA equivalents were poorly taken up by mouse tumors and tissues, except kidney, bone, and to a lesser extent, skin and lung, and were rapidly and extensively cleared from all except bone. " 08/09/2016 - "Furthermore, the in vivo biodistribution and tumor growth inhibition studies of PALA-sLDL were investigated in xenograft U87 MG tumor-bearing mice. " 01/01/2015 - "From 1994 to 2004, in the Cancer Institute Hospital, 502 patients who were surgically treated with systematic PLA and PALA were enrolled in this study. " 01/01/1980 - "Delineation of the single-agent activity of PALA in human cancer must still await results of recently activated trials."
3.	Carcinoma (Carcinomatosis) 03/01/1981 - "Phase II study of PALA in advanced large bowel carcinoma." 08/01/1985 - "Evidence presented here supports the ability of DP to potentiate PALA activity against a human ovarian carcinoma cell line. " 08/01/1985 - "In a human ovarian carcinoma cell line (2008), DP increased the activity of PALA by 1 to 2 logs in growth rate and clonogenic assays while exhibiting no cytotoxicity of its own. " 12/01/1984 - "Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. " 12/01/1984 - "PALA (NSC-224131) in advanced carcinoma of the cervix. "
4.	Leukemia 10/01/1982 - "Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors." 02/01/1996 - "Ara-C cytotoxicity to leukemic blast cells from 11 untreated patients with different types of leukemia was only modulated to a small extent by high PALA concentrations in only two cases. " 04/01/1985 - "At the clinically relevant concentration of 1 microM, dipyridamole increased the cytotoxicity of PALA against a melanoma, a colon carcinoma, a promyelocytic leukemia (HL-60), and normal marrow (CFU-GM) in clonogenic assays. " 04/01/1993 - "At the maximum tolerated doses, the antitumor activity in mice bearing advanced colon carcinoma can be summarized as follows: (a) FdUrd is significantly more active than FUra; (b) for both drugs the weekly for 3 weeks i.v. push schedule is superior to the c.i. or i.v. push daily for 4 days schedules; (c) pretreatment with PALA enhances the antitumor activity of FdUrd and FUra and resulted in 95 and 13% complete responses, respectively; (d) long-term survivors with FUra could only be achieved in the presence of PALA; in mice bearing leukemia 1210 cells, FdUrd or FUra with or without PALA exhibited no significant antitumor activity when PALA was administered in a single dose 24 h prior to fluoropyrimidine treatment; and (e) in C-26 and L1210, PALA reduced the pools of CTP and UTP equally, to about 10% of controls with significant difference in their rates of recovery." 08/01/1976 - "PALA, unlike other antimetabolites, was less effective against ascitic leukemias than against two solid tumors, B16 melanoma and Lewis lung carcinoma. "
5.	Adenocarcinoma 11/01/2001 - "Twenty-seven patients with gastrointestinal tract adenocarcinomas were treated with PALA 1266 mg/m2/15 min followed by a 72-hour infusion of FUra and LV (1750 & 500 mg/m2/day) given by fixed- or variable-rate (peak at 4:00 A.M.). " 03/15/1996 - "A 72-h exposure to PALA (> or = 25 microM) delayed the growth of human ovarian adenocarcinoma BG-1 cells by 40% compared to that of the untreated control cells. " 01/15/1991 - "5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas." 01/01/1996 - "PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial." 01/01/1996 - "In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. "

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	sparfosic acid (PALA)
3.	Leucovorin (Folinic Acid)
4.	Aspartic Acid (Aspartate)
5.	Interferons
6.	Antimetabolites
7.	Thymidine
8.	Methylthioinosine
9.	Interferon alpha-2 (Roferon-A)
10.	pyrimidine

Related Therapies and Procedures

1.	Therapeutics
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Lymph Node Excision (Lymph Node Dissection)